NCT06230731 Oxygenation in Vascular Lesions of the Colon
| NCT ID | NCT06230731 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Vascular Lesion |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-02-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate oxygenation in the colon in people with acquired vascular abnormalities in the proximal colon.
Eligibility Criteria
Inclusion Criteria: * Undergo standard of care colonoscopy * People with a history of vascular lesions of the colon * People with healthy colon * 18 - 89 years of age Exclusion Criteria: * Age \< 18 years * Age \> 90 years * People with ulcerations in at ascending colon opposite the ileocecal valve * Previous colon surgery
Contact & Investigator
Joel Pekow, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06230731 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Vascular Lesion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06230731 currently recruiting?
Yes, NCT06230731 is actively recruiting participants. Contact the research team at jpekow@bsd.uchicago.edu for enrollment information.
Where is the NCT06230731 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06230731 clinical trial?
NCT06230731 is sponsored by University of Chicago. The principal investigator is Joel Pekow, MD at University of Chicago. The trial plans to enroll 30 participants.